UNRAVELING IMMUNE PRIVILEGE

[1] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J]. NATURE, 1995, 377 (6550) : 630 - 632

[2] BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579

[3] FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J]. SCIENCE, 1995, 270 (5239) : 1189 - 1192

[4] HARA Y, 1992, J IMMUNOL, V148, P1685

[5] KAPLAN HJ, 1977, J IMMUNOL, V118, P809

[6] DO IMMUNOLOGICALLY PRIVILEGED SITES REQUIRE A FUNCTIONING SPLEEN [J]. NATURE, 1974, 251 (5475) : 553 - 554

[7] KHAW PT, 1992, INVEST OPHTH VIS SCI, V33, P3302

[8] MCLEISH W, 1989, REG IMMUNOL, V2, P235

[9] MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58

[10] LYMPHATIC DRAINAGE OF THE RAT PROSTATE AND ITS STATUS AS AN IMMUNOLOGICALLY PRIVILEGED SITE [J]. TRANSPLANTATION, 1979, 27 (02) : 127 - 132

[1] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J]. NATURE, 1995, 377 (6550) : 630 - 632

[2] BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579

[3] FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J]. SCIENCE, 1995, 270 (5239) : 1189 - 1192

[4] HARA Y, 1992, J IMMUNOL, V148, P1685

[5] KAPLAN HJ, 1977, J IMMUNOL, V118, P809

[6] DO IMMUNOLOGICALLY PRIVILEGED SITES REQUIRE A FUNCTIONING SPLEEN [J]. NATURE, 1974, 251 (5475) : 553 - 554

[7] KHAW PT, 1992, INVEST OPHTH VIS SCI, V33, P3302

[8] MCLEISH W, 1989, REG IMMUNOL, V2, P235

[9] MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58

[10] LYMPHATIC DRAINAGE OF THE RAT PROSTATE AND ITS STATUS AS AN IMMUNOLOGICALLY PRIVILEGED SITE [J]. TRANSPLANTATION, 1979, 27 (02) : 127 - 132